The Experts below are selected from a list of 294 Experts worldwide ranked by ideXlab platform
Allison B Goldfine - One of the best experts on this subject based on the ideXlab platform.
-
response to comment on goldfine et al targeting inflammation using Salsalate in patients with type 2 diabetes effects on flow mediated dilation tinsal fmd diabetes care 2013 36 4132 4139
Diabetes Care, 2014Co-Authors: Steven E Shoelson, Allison B Goldfine, Kathleen A Jablonski, Mark A CreagerAbstract:In our study to target inflammation using Salsalate in patients with type 2 diabetes, we demonstrate improvement in glycemia but no change in either flow-mediated, endothelium-dependent (FMD) or nitroglycerin-mediated, endothelium-independent dilation over 6 months in Salsalate (3.5 g/day) compared with placebo-treated patients (1). It is important to note that no adverse cardiovascular safety signal for endothelial function was demonstrated. Our findings differ from Pierce and colleagues (2,3), who demonstrated improvement in vascular function and …
-
the impact of Salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes
Diabetes Care, 2014Co-Authors: Joshua I Barzilay, Steven E Shoelson, Allison B Goldfine, Vivian Fonseca, Kathleen A Jablonski, Christopher Strauch, Vincent M MonnierAbstract:measured in patient serum samples. RESULTS Forty-eight weeks of Salsalate treatment lowered levels of HbA1c and serum furosine (P < 0.001) and CML compared with placebo. The AGEs CEL and G- 1 Ha nd MG- 1 H levels were unchanged, whereas pentosidine levels increased more than twofold (P < 0.001). Among Salsalate users, increases in adiponectin levels were associated with lower HbA1c levels during follow-up (P < 0.001). Changes in renal and inflammation factor levels were not associated with changes in levels of early or late glycation factors. Pentosidine level changes were unrelated to changes in levels of renal function, inflammation, or cytokines. CONCLUSIONS
-
targeting inflammation using Salsalate in patients with type 2 diabetes effects on flow mediated dilation tinsal fmd
Diabetes Care, 2013Co-Authors: Cyrus Desouza, Steven E Shoelson, Allison B Goldfine, Stewart J Buck, Vivian Fonseca, Yiider Ida Chen, Kathleen A Jablonski, Mark A CreagerAbstract:OBJECTIVE To test whether inhibiting inflammation with Salsalate improves endothelial function in patients with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS We conducted an ancillary study to the National Institutes of Health–sponsored, multicenter, randomized, double-masked, placebo-controlled trial evaluating the safety and efficacy of Salsalate in targeting inflammation to improve glycemia in patients with T2D. Flow-mediated, endothelium-dependent dilation (FMD) and endothelium-independent, nitroglycerin-mediated dilation (NMD) of the brachial artery were assessed at baseline and 3 and 6 months following randomization to either Salsalate 3.5 g/day or placebo. The primary end point was change in FMD at 6 months. RESULTS A total of 88 participants were enrolled in the study, and data after randomization were available for 75. Patients in the treatment and control groups had similar ages (56 years), BMI (33 kg/m2), sex (64% male), ethnicity, current treatment, and baseline HbA1c (7.7% [61 mmol/mol]). In patients treated with Salsalate versus placebo, HbA1c was reduced by 0.46% (5.0 mmol/mol; P < 0.001), fasting glucose by 16.1 mg/dL ( P < 0.001), and white blood cell count by 430 cells/µL ( P < 0.02). There was no difference in the mean change in either FMD (0.70% [95% CI −0.86 to 2.25%]; P = 0.38) or NMD (−0.59% [95% CI −2.70 to 1.51%]; P = 0.57) between the groups treated with Salsalate and placebo at 6 months. Total and LDL cholesterol were 11 and 16 mg/dL higher, respectively, and urinary albumin was 2.0 µg/mg creatinine higher in the patients treated with Salsalate compared with those treated with placebo (all P < 0.009). CONCLUSIONS Salsalate does not change FMD in peripheral conduit arteries in patients with T2D despite lowering HbA1c. This finding suggests that Salsalate does not have an effect on vascular inflammation, inflammation does not cause endothelial dysfunction in T2D, or confounding effects of Salsalate mitigate favorable effects on endothelial function.
-
salicylate Salsalate in patients with type 2 diabetes
Annals of Internal Medicine, 2013Co-Authors: Allison B Goldfine, Vivian Fonseca, Yiider Ida Chen, Kathleen A Jablonski, Myrlene A Staten, Laura Tipton, Steven E ShoelsonAbstract:Evidence suggests that Salsalate can improve glycemia in type 2 diabetes, but its efficacy and safety have not been tested using currently accepted regulatory practices. This randomized trial of pa...
-
salicylate Salsalate in patients with type 2 diabetes a randomized trial
Annals of Internal Medicine, 2013Co-Authors: Allison B Goldfine, Vivian Fonseca, Yiider Ida Chen, Kathleen A Jablonski, Myrlene A Staten, Laura Tipton, Steven E ShoelsonAbstract:Salicylate is one of the oldest drugs in clinical practice, with documented use of relevant plant extracts for treating pain and inflammation dating back at least 3500 years (1). Nevertheless, its medicinal properties and mechanisms of action remain incompletely understood. Chemically pure forms were introduced during the 19th century (2, 3), but by the century’s end, salicylate had been acetylated by chemists to yield aspirin, which became the most used—and most marketed—drug in history (1, 4). The mechanism of aspirin is well-established; the acetyl group covalently modifies a serine at the active site of the cyclooxygenase (COX) enzymes (5), making it the prototypic nonsteroidal anti-inflammatory drug (NSAID). Salicylate lacks an acetyl group and, thus, must have a different mechanism of action. Neither salicylate nor prodrugs, including Salsalate or trilisate, which are marketed for pain, have been tested for efficacy and safety under what regulatory agencies now consider to be current standard practice in clinical trials. Interest in salicylate was renewed after suggestions that it lowers blood glucose in type 2 diabetes mellitus (T2DM) (6). Results from proof-of-principle studies using Salsalate in patients with T2DM demonstrated reduced blood glucose, triglyceride, free fatty acid, and C-reactive protein concentrations; improved glucose utilization during euglycemic hyperinsulinemic clamp (defined as the glucose infusion rate required to maintain euglycemia at steady state during insulin infusion); and increased circulating insulin and adiponectin levels (7). The National Institutes of Health–sponsored TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) trials determine whether this generic and inexpensive drug is safe, tolerated, and efficacious in diabetes. Stage 1, a dose-ranging study, was reported (8); stage 2 of TINSAL-T2D is a larger study to assess the magnitude and durability of glycemic efficacy over 1 year, tolerability, and an array of safety variables relevant to patients with diabetes.
Steven E Shoelson - One of the best experts on this subject based on the ideXlab platform.
-
Salsalate improves glycaemia in overweight persons with diabetes risk factors of stable statin treated cardiovascular disease a 30 month randomized placebo controlled trial
Diabetes Obesity and Metabolism, 2017Co-Authors: Thomas H Hauser, Ninad Salastekar, Ernst J Schaefer, Tanvi Desai, Kristen Fowler, Stacey Joseph, Steven E ShoelsonAbstract:Obesity related sub-acute chronic inflammation contributes to type 2 diabetes and atherosclerosis 1,2. Multiple studies target inflammation to reduce dysglycemia and/or coronary heart disease (CHD) using diverse anti-inflammatory approaches. Several show Salsalate, a pro-drug of salicylate, improves glycemia in type 2 diabetes, obesity, or impaired glucose tolerance. Durability of glycemic efficacy and safety of Salsalate remains less well understood.
-
response to comment on goldfine et al targeting inflammation using Salsalate in patients with type 2 diabetes effects on flow mediated dilation tinsal fmd diabetes care 2013 36 4132 4139
Diabetes Care, 2014Co-Authors: Steven E Shoelson, Allison B Goldfine, Kathleen A Jablonski, Mark A CreagerAbstract:In our study to target inflammation using Salsalate in patients with type 2 diabetes, we demonstrate improvement in glycemia but no change in either flow-mediated, endothelium-dependent (FMD) or nitroglycerin-mediated, endothelium-independent dilation over 6 months in Salsalate (3.5 g/day) compared with placebo-treated patients (1). It is important to note that no adverse cardiovascular safety signal for endothelial function was demonstrated. Our findings differ from Pierce and colleagues (2,3), who demonstrated improvement in vascular function and …
-
the impact of Salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes
Diabetes Care, 2014Co-Authors: Joshua I Barzilay, Steven E Shoelson, Allison B Goldfine, Vivian Fonseca, Kathleen A Jablonski, Christopher Strauch, Vincent M MonnierAbstract:measured in patient serum samples. RESULTS Forty-eight weeks of Salsalate treatment lowered levels of HbA1c and serum furosine (P < 0.001) and CML compared with placebo. The AGEs CEL and G- 1 Ha nd MG- 1 H levels were unchanged, whereas pentosidine levels increased more than twofold (P < 0.001). Among Salsalate users, increases in adiponectin levels were associated with lower HbA1c levels during follow-up (P < 0.001). Changes in renal and inflammation factor levels were not associated with changes in levels of early or late glycation factors. Pentosidine level changes were unrelated to changes in levels of renal function, inflammation, or cytokines. CONCLUSIONS
-
targeting inflammation using Salsalate in patients with type 2 diabetes effects on flow mediated dilation tinsal fmd
Diabetes Care, 2013Co-Authors: Cyrus Desouza, Steven E Shoelson, Allison B Goldfine, Stewart J Buck, Vivian Fonseca, Yiider Ida Chen, Kathleen A Jablonski, Mark A CreagerAbstract:OBJECTIVE To test whether inhibiting inflammation with Salsalate improves endothelial function in patients with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS We conducted an ancillary study to the National Institutes of Health–sponsored, multicenter, randomized, double-masked, placebo-controlled trial evaluating the safety and efficacy of Salsalate in targeting inflammation to improve glycemia in patients with T2D. Flow-mediated, endothelium-dependent dilation (FMD) and endothelium-independent, nitroglycerin-mediated dilation (NMD) of the brachial artery were assessed at baseline and 3 and 6 months following randomization to either Salsalate 3.5 g/day or placebo. The primary end point was change in FMD at 6 months. RESULTS A total of 88 participants were enrolled in the study, and data after randomization were available for 75. Patients in the treatment and control groups had similar ages (56 years), BMI (33 kg/m2), sex (64% male), ethnicity, current treatment, and baseline HbA1c (7.7% [61 mmol/mol]). In patients treated with Salsalate versus placebo, HbA1c was reduced by 0.46% (5.0 mmol/mol; P < 0.001), fasting glucose by 16.1 mg/dL ( P < 0.001), and white blood cell count by 430 cells/µL ( P < 0.02). There was no difference in the mean change in either FMD (0.70% [95% CI −0.86 to 2.25%]; P = 0.38) or NMD (−0.59% [95% CI −2.70 to 1.51%]; P = 0.57) between the groups treated with Salsalate and placebo at 6 months. Total and LDL cholesterol were 11 and 16 mg/dL higher, respectively, and urinary albumin was 2.0 µg/mg creatinine higher in the patients treated with Salsalate compared with those treated with placebo (all P < 0.009). CONCLUSIONS Salsalate does not change FMD in peripheral conduit arteries in patients with T2D despite lowering HbA1c. This finding suggests that Salsalate does not have an effect on vascular inflammation, inflammation does not cause endothelial dysfunction in T2D, or confounding effects of Salsalate mitigate favorable effects on endothelial function.
-
salicylate Salsalate in patients with type 2 diabetes
Annals of Internal Medicine, 2013Co-Authors: Allison B Goldfine, Vivian Fonseca, Yiider Ida Chen, Kathleen A Jablonski, Myrlene A Staten, Laura Tipton, Steven E ShoelsonAbstract:Evidence suggests that Salsalate can improve glycemia in type 2 diabetes, but its efficacy and safety have not been tested using currently accepted regulatory practices. This randomized trial of pa...
Matthew S. Yorek - One of the best experts on this subject based on the ideXlab platform.
-
effect of dietary content of menhaden oil with or without Salsalate on neuropathic endpoints in high fat fed low dose streptozotocin treated sprague dawley rats
Experimental Diabetes Research, 2018Co-Authors: Eric P. Davidson, Matthew S. Yorek, Lawrence J. Coppey, Hanna Shevalye, Alexander ObrosovAbstract:In this study, we wanted to extend our investigation of the efficacy of fish oil with or without Salsalate on vascular and neural complications using a type 2 diabetic rat model. Four weeks after the onset of hyperglycemia, diabetic rats were treated via the diet with 3 different amounts of menhaden oil with or without Salsalate for 12 weeks. Afterwards, vascular reactivity of epineurial arterioles and neuropathy-related endpoints were examined. The addition of Salsalate to high-fat diets enriched with 10% or 25% kcal of menhaden oil protected vascular reactivity to acetylcholine and calcium gene-related peptide, motor and sensory nerve conduction velocity, thermal nociception, intraepidermal nerve fiber density, and cornea sensitivity to a greater extent than 10% or 25% menhaden oil alone. Vascular and neural function was maximally protected with diet containing 45% kcal as menhaden oil, and adding Salsalate did not provide any additional benefit. Salsalate alone in the high-fat diet of diabetic rats provided minimal protection/improvement of vascular and neural dysfunction. These studies imply that dietary Salsalate in combination with lower amounts of menhaden oil can provide greater benefit toward diabetes-induced vascular and neural impairment than menhaden oil alone.
-
effect of treatment with Salsalate menhaden oil combination of Salsalate and menhaden oil or resolvin d1 of c57bl 6j type 1 diabetic mouse on neuropathic endpoints
Journal of Nutrition and Metabolism, 2016Co-Authors: Hanna Shevalye, Lawrence J. Coppey, Alexander Obrosov, Randy H. Kardon, Matthew S. YorekAbstract:Aims. In this study a streptozotocin induced type 1 diabetes mouse model was used to assess the effectiveness of Salsalate, menhaden oil, the combination of Salsalate and menhaden oil, or resolvin D1 on neuropathic endpoints. Materials and Methods. Changes in body weight, blood glucose, serum markers for triglycerides, free fatty acids, cholesterol, and resolvin D1, motor and sensory nerve conduction velocities and thermal sensitivity were assessed, as well as performing in vivo confocal microscopy of subepithelial corneal nerves and immunohistochemistry of nerves in the cornea and foot pad. Results. Diabetic animals failed to gain weight and had elevated blood glucose levels. Diabetic mice had slowed nerve conduction velocity, reduced innervation of the foot pad and cornea subepithelial and epithelial layers, and reduced thermal sensitivity. Monotherapy treatment with Salsalate, menhaden oil, and resolvin D1 reduced the pathological signs of diabetic neuropathy. The combination of Salsalate and menhaden oil also reduced signs of pathology and generated elevated plasma levels of resolvin D1 compared to other groups. Conclusions. Additional studies are needed to determine whether the combination of Salsalate and menhaden oil may be more efficacious than monotherapy alone for the treatment of diabetic peripheral neuropathy.
Kathleen A Jablonski - One of the best experts on this subject based on the ideXlab platform.
-
response to comment on goldfine et al targeting inflammation using Salsalate in patients with type 2 diabetes effects on flow mediated dilation tinsal fmd diabetes care 2013 36 4132 4139
Diabetes Care, 2014Co-Authors: Steven E Shoelson, Allison B Goldfine, Kathleen A Jablonski, Mark A CreagerAbstract:In our study to target inflammation using Salsalate in patients with type 2 diabetes, we demonstrate improvement in glycemia but no change in either flow-mediated, endothelium-dependent (FMD) or nitroglycerin-mediated, endothelium-independent dilation over 6 months in Salsalate (3.5 g/day) compared with placebo-treated patients (1). It is important to note that no adverse cardiovascular safety signal for endothelial function was demonstrated. Our findings differ from Pierce and colleagues (2,3), who demonstrated improvement in vascular function and …
-
the impact of Salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes
Diabetes Care, 2014Co-Authors: Joshua I Barzilay, Steven E Shoelson, Allison B Goldfine, Vivian Fonseca, Kathleen A Jablonski, Christopher Strauch, Vincent M MonnierAbstract:measured in patient serum samples. RESULTS Forty-eight weeks of Salsalate treatment lowered levels of HbA1c and serum furosine (P < 0.001) and CML compared with placebo. The AGEs CEL and G- 1 Ha nd MG- 1 H levels were unchanged, whereas pentosidine levels increased more than twofold (P < 0.001). Among Salsalate users, increases in adiponectin levels were associated with lower HbA1c levels during follow-up (P < 0.001). Changes in renal and inflammation factor levels were not associated with changes in levels of early or late glycation factors. Pentosidine level changes were unrelated to changes in levels of renal function, inflammation, or cytokines. CONCLUSIONS
-
targeting inflammation using Salsalate in patients with type 2 diabetes effects on flow mediated dilation tinsal fmd
Diabetes Care, 2013Co-Authors: Cyrus Desouza, Steven E Shoelson, Allison B Goldfine, Stewart J Buck, Vivian Fonseca, Yiider Ida Chen, Kathleen A Jablonski, Mark A CreagerAbstract:OBJECTIVE To test whether inhibiting inflammation with Salsalate improves endothelial function in patients with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS We conducted an ancillary study to the National Institutes of Health–sponsored, multicenter, randomized, double-masked, placebo-controlled trial evaluating the safety and efficacy of Salsalate in targeting inflammation to improve glycemia in patients with T2D. Flow-mediated, endothelium-dependent dilation (FMD) and endothelium-independent, nitroglycerin-mediated dilation (NMD) of the brachial artery were assessed at baseline and 3 and 6 months following randomization to either Salsalate 3.5 g/day or placebo. The primary end point was change in FMD at 6 months. RESULTS A total of 88 participants were enrolled in the study, and data after randomization were available for 75. Patients in the treatment and control groups had similar ages (56 years), BMI (33 kg/m2), sex (64% male), ethnicity, current treatment, and baseline HbA1c (7.7% [61 mmol/mol]). In patients treated with Salsalate versus placebo, HbA1c was reduced by 0.46% (5.0 mmol/mol; P < 0.001), fasting glucose by 16.1 mg/dL ( P < 0.001), and white blood cell count by 430 cells/µL ( P < 0.02). There was no difference in the mean change in either FMD (0.70% [95% CI −0.86 to 2.25%]; P = 0.38) or NMD (−0.59% [95% CI −2.70 to 1.51%]; P = 0.57) between the groups treated with Salsalate and placebo at 6 months. Total and LDL cholesterol were 11 and 16 mg/dL higher, respectively, and urinary albumin was 2.0 µg/mg creatinine higher in the patients treated with Salsalate compared with those treated with placebo (all P < 0.009). CONCLUSIONS Salsalate does not change FMD in peripheral conduit arteries in patients with T2D despite lowering HbA1c. This finding suggests that Salsalate does not have an effect on vascular inflammation, inflammation does not cause endothelial dysfunction in T2D, or confounding effects of Salsalate mitigate favorable effects on endothelial function.
-
salicylate Salsalate in patients with type 2 diabetes
Annals of Internal Medicine, 2013Co-Authors: Allison B Goldfine, Vivian Fonseca, Yiider Ida Chen, Kathleen A Jablonski, Myrlene A Staten, Laura Tipton, Steven E ShoelsonAbstract:Evidence suggests that Salsalate can improve glycemia in type 2 diabetes, but its efficacy and safety have not been tested using currently accepted regulatory practices. This randomized trial of pa...
-
salicylate Salsalate in patients with type 2 diabetes a randomized trial
Annals of Internal Medicine, 2013Co-Authors: Allison B Goldfine, Vivian Fonseca, Yiider Ida Chen, Kathleen A Jablonski, Myrlene A Staten, Laura Tipton, Steven E ShoelsonAbstract:Salicylate is one of the oldest drugs in clinical practice, with documented use of relevant plant extracts for treating pain and inflammation dating back at least 3500 years (1). Nevertheless, its medicinal properties and mechanisms of action remain incompletely understood. Chemically pure forms were introduced during the 19th century (2, 3), but by the century’s end, salicylate had been acetylated by chemists to yield aspirin, which became the most used—and most marketed—drug in history (1, 4). The mechanism of aspirin is well-established; the acetyl group covalently modifies a serine at the active site of the cyclooxygenase (COX) enzymes (5), making it the prototypic nonsteroidal anti-inflammatory drug (NSAID). Salicylate lacks an acetyl group and, thus, must have a different mechanism of action. Neither salicylate nor prodrugs, including Salsalate or trilisate, which are marketed for pain, have been tested for efficacy and safety under what regulatory agencies now consider to be current standard practice in clinical trials. Interest in salicylate was renewed after suggestions that it lowers blood glucose in type 2 diabetes mellitus (T2DM) (6). Results from proof-of-principle studies using Salsalate in patients with T2DM demonstrated reduced blood glucose, triglyceride, free fatty acid, and C-reactive protein concentrations; improved glucose utilization during euglycemic hyperinsulinemic clamp (defined as the glucose infusion rate required to maintain euglycemia at steady state during insulin infusion); and increased circulating insulin and adiponectin levels (7). The National Institutes of Health–sponsored TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) trials determine whether this generic and inexpensive drug is safe, tolerated, and efficacious in diabetes. Stage 1, a dose-ranging study, was reported (8); stage 2 of TINSAL-T2D is a larger study to assess the magnitude and durability of glycemic efficacy over 1 year, tolerability, and an array of safety variables relevant to patients with diabetes.
Vivian Fonseca - One of the best experts on this subject based on the ideXlab platform.
-
the impact of Salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes
Diabetes Care, 2014Co-Authors: Joshua I Barzilay, Steven E Shoelson, Allison B Goldfine, Vivian Fonseca, Kathleen A Jablonski, Christopher Strauch, Vincent M MonnierAbstract:measured in patient serum samples. RESULTS Forty-eight weeks of Salsalate treatment lowered levels of HbA1c and serum furosine (P < 0.001) and CML compared with placebo. The AGEs CEL and G- 1 Ha nd MG- 1 H levels were unchanged, whereas pentosidine levels increased more than twofold (P < 0.001). Among Salsalate users, increases in adiponectin levels were associated with lower HbA1c levels during follow-up (P < 0.001). Changes in renal and inflammation factor levels were not associated with changes in levels of early or late glycation factors. Pentosidine level changes were unrelated to changes in levels of renal function, inflammation, or cytokines. CONCLUSIONS
-
targeting inflammation using Salsalate in patients with type 2 diabetes effects on flow mediated dilation tinsal fmd
Diabetes Care, 2013Co-Authors: Cyrus Desouza, Steven E Shoelson, Allison B Goldfine, Stewart J Buck, Vivian Fonseca, Yiider Ida Chen, Kathleen A Jablonski, Mark A CreagerAbstract:OBJECTIVE To test whether inhibiting inflammation with Salsalate improves endothelial function in patients with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS We conducted an ancillary study to the National Institutes of Health–sponsored, multicenter, randomized, double-masked, placebo-controlled trial evaluating the safety and efficacy of Salsalate in targeting inflammation to improve glycemia in patients with T2D. Flow-mediated, endothelium-dependent dilation (FMD) and endothelium-independent, nitroglycerin-mediated dilation (NMD) of the brachial artery were assessed at baseline and 3 and 6 months following randomization to either Salsalate 3.5 g/day or placebo. The primary end point was change in FMD at 6 months. RESULTS A total of 88 participants were enrolled in the study, and data after randomization were available for 75. Patients in the treatment and control groups had similar ages (56 years), BMI (33 kg/m2), sex (64% male), ethnicity, current treatment, and baseline HbA1c (7.7% [61 mmol/mol]). In patients treated with Salsalate versus placebo, HbA1c was reduced by 0.46% (5.0 mmol/mol; P < 0.001), fasting glucose by 16.1 mg/dL ( P < 0.001), and white blood cell count by 430 cells/µL ( P < 0.02). There was no difference in the mean change in either FMD (0.70% [95% CI −0.86 to 2.25%]; P = 0.38) or NMD (−0.59% [95% CI −2.70 to 1.51%]; P = 0.57) between the groups treated with Salsalate and placebo at 6 months. Total and LDL cholesterol were 11 and 16 mg/dL higher, respectively, and urinary albumin was 2.0 µg/mg creatinine higher in the patients treated with Salsalate compared with those treated with placebo (all P < 0.009). CONCLUSIONS Salsalate does not change FMD in peripheral conduit arteries in patients with T2D despite lowering HbA1c. This finding suggests that Salsalate does not have an effect on vascular inflammation, inflammation does not cause endothelial dysfunction in T2D, or confounding effects of Salsalate mitigate favorable effects on endothelial function.
-
salicylate Salsalate in patients with type 2 diabetes
Annals of Internal Medicine, 2013Co-Authors: Allison B Goldfine, Vivian Fonseca, Yiider Ida Chen, Kathleen A Jablonski, Myrlene A Staten, Laura Tipton, Steven E ShoelsonAbstract:Evidence suggests that Salsalate can improve glycemia in type 2 diabetes, but its efficacy and safety have not been tested using currently accepted regulatory practices. This randomized trial of pa...
-
salicylate Salsalate in patients with type 2 diabetes a randomized trial
Annals of Internal Medicine, 2013Co-Authors: Allison B Goldfine, Vivian Fonseca, Yiider Ida Chen, Kathleen A Jablonski, Myrlene A Staten, Laura Tipton, Steven E ShoelsonAbstract:Salicylate is one of the oldest drugs in clinical practice, with documented use of relevant plant extracts for treating pain and inflammation dating back at least 3500 years (1). Nevertheless, its medicinal properties and mechanisms of action remain incompletely understood. Chemically pure forms were introduced during the 19th century (2, 3), but by the century’s end, salicylate had been acetylated by chemists to yield aspirin, which became the most used—and most marketed—drug in history (1, 4). The mechanism of aspirin is well-established; the acetyl group covalently modifies a serine at the active site of the cyclooxygenase (COX) enzymes (5), making it the prototypic nonsteroidal anti-inflammatory drug (NSAID). Salicylate lacks an acetyl group and, thus, must have a different mechanism of action. Neither salicylate nor prodrugs, including Salsalate or trilisate, which are marketed for pain, have been tested for efficacy and safety under what regulatory agencies now consider to be current standard practice in clinical trials. Interest in salicylate was renewed after suggestions that it lowers blood glucose in type 2 diabetes mellitus (T2DM) (6). Results from proof-of-principle studies using Salsalate in patients with T2DM demonstrated reduced blood glucose, triglyceride, free fatty acid, and C-reactive protein concentrations; improved glucose utilization during euglycemic hyperinsulinemic clamp (defined as the glucose infusion rate required to maintain euglycemia at steady state during insulin infusion); and increased circulating insulin and adiponectin levels (7). The National Institutes of Health–sponsored TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) trials determine whether this generic and inexpensive drug is safe, tolerated, and efficacious in diabetes. Stage 1, a dose-ranging study, was reported (8); stage 2 of TINSAL-T2D is a larger study to assess the magnitude and durability of glycemic efficacy over 1 year, tolerability, and an array of safety variables relevant to patients with diabetes.
-
the effects of Salsalate on glycemic control in patients with type 2 diabetes
Annals of Internal Medicine, 2010Co-Authors: Allison B Goldfine, Vivian Fonseca, Kathleen A Jablonski, Laura Pyle, Myrlene A Staten, Steven E ShoelsonAbstract:Small studies have shown that Salsalate reduces blood glucose concentration. Goldfine and associates randomly assigned patients with type 2 diabetes to 1 of 3 doses of Salsalate or placebo. Salsala...
